Provided by Tiger Fintech (Singapore) Pte. Ltd.

crane

152.73
-0.4400-0.29%
Pre-market: 152.01-0.7200-0.47%04:00 EDT
Volume:1.79M
Turnover:272.78M
Market Cap:8.69B
PE:30.22
High:152.93
Open:151.57
Low:150.41
Close:153.17
Loading ...

CR Construction Group Holdings Full Year 2024 Earnings: EPS: HK$0.11 (vs HK$0.14 in FY 2023)

Simply Wall St.
·
22 Mar

BioInvent’s anti-TNFR2 antibody BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum

ACCESS Newswire
·
21 Mar

Press Release: SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Dow Jones
·
21 Mar

Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment

Benzinga
·
21 Mar

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

ACCESS Newswire
·
20 Mar

CR Construction Group Announces Final Dividend for 2024

TIPRANKS
·
20 Mar

BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma

ACCESS Newswire
·
20 Mar

CR Double-Crane Pharmaceutical 2024 Profit Down 3%; Shares Decline 3%

MT Newswires Live
·
20 Mar

Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025

PR Newswire
·
19 Mar

CR Double-Crane Reports 2024 Financial Results with Dividend Proposal

TIPRANKS
·
19 Mar

Kratos Defense begins building IPIF in Crane, Indiana to support MACH-TB

TIPRANKS
·
19 Mar

Press Release: INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Dow Jones
·
19 Mar

Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®

PR Newswire
·
18 Mar

Crane Company (CR): Among the Best Reddit Stocks to Invest In

Insider Monkey
·
18 Mar

Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia

PR Newswire
·
17 Mar

INAB: Introducing INB-600, A γδ T Cell Engager Platform

Zacks Small Cap Research
·
17 Mar